Best pharmaceutical companies in California

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland.

Allergan, Inc., a subsidiary of Allergan plc., operates as a specialty pharmaceutical company in the United States and internationally. The company offers its products under the Botox and Restasis brands. It markets products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. Allergan, Inc. was founded in 1948 and is based in Irvine, California, with operations in approximately 100 countries.

Nektar Therapeutics, founded in 1990, is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines. Their drugs are used for the treatments of cancer, auto-immune disease and chronic pain. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. The company employs a team of about 500 dedicated scientists, clinicians and employees that discover medicines for patients with debilitating diseases.

SantenUSA.com - a specialty pharmaceutical offering ophthalmic products & research for retinal disorders, glaucoma, and other eye diseases.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc. (Astellas), the Company is developing MDV3100 for multiple stages of advanced prostate cancer. As of December 31, 2011, it completed a Phase III trial in the latest stage. The Company's three subsidiaries include Medivation Prostate Therapeutics, Inc. (MPT), Medivation Neurology, Inc. (MNI) and Medivation Technologies, Inc. (MTI). MPT holds the Company's MDV300 series technology, which is in development for the treatment of advanced prostate cancer, and MTI holds its earlier stage technologies. MNI holds its dimebon technology, which was in development for the treatment of Alzheimer's disease and Huntington disease.

Roche Holdings, Inc., together with its subsidiaries, manufactures and sells pharmaceuticals and diagnostics. Its Pharmaceuticals division provides various prescription pharmaceutical products, such as Rituxan, Avastin, Herceptin, Perjeta, Xolair, Actemra, Lucentis, and Tamiflu. The company s Diagnostics division offers point of care solutions, molecular diagnostics, tissue diagnostics, and immunodiagnostics, as well as diagnostic instruments, reagents, and consumables. It primarily serves the U.S. national wholesale distributors. The company was founded in 1987 and is based in South San Francisco, California. Roche Holdings, Inc. is a subsidiary of Roche Finance Ltd.

Purchase influenza vaccines, IVIG, albumin, immune globulin, hyperimmunes, oncology, and coagulation/factor products from a biopharmaceutical supply chain professional

Astex Pharmaceuticals develops oncology drugs that fights against cancer. It develops a proprietary pipeline of novel anti-cancer therapies and has a number of partnered products being developed under collaborations with pharmaceutical companies. Based in Dublin, California, Astex Pharmaceuticals was founded in 1999.

Quidel was founded in 1979 and eventually launched its first product in 1984. It is a California-based leading diagnostic healthcare manufacturer serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.

Prometheus Laboratories Inc. provide diagnostics which enable unique health solutions. Considered as a leader of precision healthcare in gastroenterolgy, it develops and brings to the market diagnostic tests that help physicians provide the highest level of patient care. Since 2011, it has been a part of Nestle Health Science, aiming to change the way people approach and manage their health.

Nexgen Pharma is a specialty pharmaceutical company that provides development and manufacturing services for Rx, OTC drugs as well as custom dietary supplement formulations. Nexgen Pharma has over 80 years of manufacturing experience with a rigorous commitment to quality and customer service.

Tandem Diabetes Care, Inc. develops medical devices for the treatment of diabetes. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges. The company focuses on insulin infusion therapy. Tandem Diabetes Care, Inc. was incorporated in 2006 and is based in San Diego, California.

IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery.

Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Corium International is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development.

Life Alert is a medical alert system which is designed to protect seniors and all family members in a home health emergency. Individuals can connect to the system through medical emergencies, shower emergencies, intrusion emergencies, life alert mobile, and mobile application. The services can help seniors remain independent and possibly avoid a retirement home by sending help fast in the event of a medical, fall, shower, and home invasion emergencies. Life Alert is based in the United States and the company was founded in 1987 by Zohar Loshitzer.

Therapeutics, Inc. is a drug development company dedicated to innovation. We focus on dermatology-related areas of medicine and provide unwavering service and commitment to moving products from concept to the bench top, to proof-of-concept and then, if appropriate, through clinical development with regulatory review and approval.

Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company's primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.

MAP Pharmaceuticals, Inc., a development stage company, focuses on developing novel inhalation therapies for respiratory and systemic diseases. It has various proprietary product candidates in clinical development, including Unit Dose Budesonide for pediatric asthma in children from six months to eight years of age and MAP0004 for migraine. The company's product portfolio also includes MAP0005 for the treatment of adolescent and adult asthma, and chronic obstructive pulmonary disease; and MAP0001 for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Mountain View, California.

The Corporate Victor page is designed to communicate with both our employees and our customers the work that we are doing around the State of California. As a service provider with multiple offices and a broad set of mental health services, it is not a...

Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. The company principally offers Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. Its other clinical product candidates include ABI-008, a phase II solvent-free and Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a phase I nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity; and Coroxane, a phase II nanometer-sized paclitaxel for coronary restenosis and peripheral artery restenosis. Abraxis BioScience has strategic relationships with Taiho Pharmaceutical Co., Ltd.; Biocon Limited; Green Cross Corporation; Specialised Therapeutics of Australia, Pty Ltd.; and ProMetic Life Sciences Inc. The company was formerly known as New Abraxis, Inc. and changed its name to Abraxis BioScience, Inc. in November 2007. Abraxis BioScience, Inc. is based in Los Angeles, California. In 2010, Abraxis BioScience was acquired by Celgene Corp .

VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate Ligand revenue.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC's second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC's scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.

OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.

VasoNova, Inc. manufactures and markets medical devices. It develops a self-guided PICC catheter. The company is based in Sunnyvale, California.

ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

mission of Imprimis Pharmaceuticals is to improve patient health and their quality of life by working with innovative compounding pharmacists and drug developers to commercialize compounded drug formulations. We are also focused on leveraging Accudel, a patented topical drug delivery platform, that enables highly targeted site specific treatment. Why are we focused on topical drug delivery? Because delivering medicines locally to a specific site in the body instead of swallowing a pill, for example, allows for a reduction in problematic side effects often associated with systemic delivery. We believe our focus on compounded drug formulations and topical drug delivery improves patient health and quality of life.

Watson Laboratories, Inc. manufactures pharmaceutical drugs. The company was incorporated in 1992 and is based in Corona, California. Watson Laboratories, Inc. operates as a subsidiary of Allergan plc.

GMP Certified Dietary Supplement Contract Manufacturer - softgels, tablets, capsules, powders, teas, custom formulations, raw material sourcing, packaging

Exo handheld ultrasound platform and AI for imaging and therapeutic applications. Exo is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes.

SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul South Korea and Financial District, San Francisco. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVE™ platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. 2003. Jennerex, Inc. (San Francisco, USA) was established. 2014. SillaJen acquires Jennerex, Inc. 2015. In April 2015. SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer. 2015. In October 2015, SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products." 2016. In January 2016, SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer. In December 2016. SillaJen is listed on KOSDAQ market in South Korea. 2017. In may 2017, Sillajen signs collaborative agreement with Regeneron Pharmaceuticals for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors. In July 2017, SillaJen received approval from the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancer. In Aug 2017, Sillajen signs collaborative agreement with the National Cancer Institute for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors.

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DosePro™, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Developing medicines with the potential to change lives. Creating transformative medicine for rare liver diseas.

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB™, the Company's proprietary antibody drug discovery platform.

Scios Inc. is a pharmaceutical company developing drugs for the treatment of cardiovascular and inflammatory diseases. The company is a subsidiary of Johnson & Johnson. The company's portfolio of drugs includes NatrecorO, a promising drug for heart failure. Scios Inc. was founded in 1981 and is based in California.

Sight Sciences uses a computer-based device designed for treatment of eye disease. Sight Sciences' devices and non-invasive dry eye products are used for glaucoma procedures or in combination with cataract surgery using the same clear corneal incision, assisting ophthalmologists and optometrists to address the underlying physiology of ophthalmic disease.

Statement is “to provide high quality, family-centered, culturally competent behavioral health and human services.

Alza Corporation was a pharmaceutical and medical systems company.

Cerebral is a mental health telemedicine company offerint high-quality medication management, counseling, and therapy for anxiety and depression

Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. In addition to the Corporate Headquarters, Amphastar has five manufacturing facilities located in the United States, China and Europe along with a state-of-the-art New Drug Research Center. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry.

Metronom Health, Inc. develops and markets continuous glucose monitoring systems for diabetes management. The company was incorporated in 2009 and is based in Laguna Hills, California.

HUYA Bioscience started in 2004 with a vision. I wanted to identify and add value to the wealth of therapeutic opportunities from Chinese institutes and universities. In the few intervening years, HUYA has grown to be the leader in globalizing China's pharmaceutical innovation. Meeting the challenge of tomorrow's unmet medical needs requires utilizing the talents of Chinese researchers and helping to move their discoveries forward. The HUYA team both in San Diego and their eight China offices is committed to building relationships that enable candidate compounds to be more accessible internationally. With diverse approaches including in-licensing, alliances with large pharmaceutical companies, co-development and research funding, HUYA is poised to bring China's health care discoveries to the world.

Design, development, manufacture, sale, service, lease, import and export of ophthalmic surgical devices, examination and diagnostic devices, electronic medical record/ practice management/ medical filing systems, intra-ocular lenses.

Irvine Pharmaceutical Service Inc. is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Irvine provides full cGMP specialized product development service such as preformulation/formulation, analytical development, parenteral manufacturing, stability storage and complete analytical CMC testing. More information: www.irvinepharma.com

Strategic consulting, clinical operations, biometrics and medical writing services for pharmaceutical and biotechnology companies. InClin is dedicated to serving the product development needs of pharmaceutical and biotechnology companies.

Suneva Medical, Inc. is a privately held medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. It provides a novel and differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. The company's flagship brand, Bellafill is the only dermal filler on the market with five-year safety and efficacy data, and the only dermal filler approved for the correction of facial acne scars. The Company was formed in April 2009 and is backed by HealthCare Royalty Partners, a global healthcare investment firm with $1.5 billion in capital under management. HC Royalty's investment strategy is to make long-term investments in unique and promising healthcare products and companies. The firm has a proven track record of success. The Suneva Medical product portfolio focuses on compelling, differentiated products that deliver high patient satisfaction and represent a significant business opportunity to its practice partners.

Pharmaco-Kinesis Corporation (PKC) is a high-technology medical device company that aims to optimize the healing of the human body through the implementation of its proprietary Smart Drug Delivery Systems™ (SDDS™) and related products.

Avail Medsystems is a Health Care Company and developer of software intended to digitize physical presence in operating rooms. Avail Medsystems is specializing in designing and manufacturing medical devices that can be utilized during procedures for video conferencing with other medical professionals. The company was founded in 2018 and based in Palo Alto, California.

Hisamitsu Pharmaceutical Co., Inc., headquartered in Saga and Tokyo, Japan is a pharmaceutical company that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch.

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Inari Medical is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. It has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism. The company was founded in 2011 and is headquartered in Irvine, California.

Universal Packaging Systems, Inc. operates as a contract manufacturer and packager of fragrance, cosmetic products, and over the counter pharmaceuticals. It provides product development/technical services; filling of personal care, over the counter, and fragrances/alcohol products; and turnkey and secondary assembly services. Universal Packaging Systems, Inc. was founded in 1987 and is based in Chino, California.

Captek Softgel International, Inc. (CSI) is a privately-owned, FDA registered and audited, GMP-certified, full service contract manufacturer of custom dietary supplement formulations. CSI features high efficiency encapsulation lines operating 24/5, capable of producing over three billion softgels annually. The facility encompasses approximately 85,000 square feet of production, analytical laboratory, pilot laboratory, and warehousing space. Captek fully complies with FDA cGMPs and has been independently certified by NSF International.

Gynesonics is a women's healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions.

StudyKIK is the leading website where855 500 0217 clinical trial companies list their studies and eager volunteers find them to sign up instantly. It has never been easier to search and find clinical trials of all therapeutic types! Give it a try… you may be surprised with the studies you find! StudyKIK's mission is change lives by helping new treatments come to market faster and to enable anyone who wants to volunteer for a research study to easily search.

Jaguar Animal Health is committed to bringing naturally derived important health solutions to all animals of the world, as proprietary pharmaceuticals, food additives, and nutraceuticals. Jaguar merges the high-value business model of companion and competitive animal care with the higher-volume economically driven business model applied to the food/farm animal marketplace. Jaguar expects to introduce its first products for animals experiencing watery diarrhea in 2014, both under its own label and in conjunction with private-label marketers.

Insightra Medical was founded in 2001 as a medical device innovator. The charter was to create niche surgical products based on proprietary designs. Since then, the company has developed into a strong general surgery company with a focus on inguinal and ventral hernia.

Cotherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, our lead product candidate, is an inhaled formulation of iloprost.

Edgewood Center for Children and Families helps children and families to overcome severe challenges, strengthening families and restoring hope.

Tusker Medical is a medical platform focused on delivering innovative technology to ear, nose, and throat surgeons and their patients. The company is developing a suite of pediatric-focused technologies designed to enable placement of tubes in the comfort of an office environment, thus avoiding general anesthetics. Tusker Medical's suite of pediatric-focused technologies includes an iontophoresis system to safely and reliably provide needle-free local anesthesia to the tympanic membrane and a tube delivery system designed to provide automated single-button delivery of the tympanostomy tube, enabling placement of tubes within the comfort of an office environment, eliminating the need for general anesthetics. It was founded in 2016 and is headquartered in Menlo Park, California, United States.

Carbon Health is the technology-enabled healthcare provider designed from the ground up to put patient-care first. By combining technology with modern clinics, it delivers a uniquely seamless experience from virtual care to in-person care to meet patients where they are. Through its end-to-end technology platform that dramatically improves clinical efficiency, Carbon Health has rebuilt care delivery to enable physicians to focus on care and spend more time with their patients. Patient experience is further enhanced through the Carbon Health mobile app where patients can easily see all of their health records, book appointments, make payments or conduct a video visit from anywhere. With a team of engineers, designers and expert physicians, Carbon Health removes the boundaries to high-quality, transparent and personal care and envisions making patient-centric, world-class care accessible and a reality for everyone. Carbon Health is headquartered in San Francisco with clinics across California.

Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet medical needs. Their application of novel technologies is designed to enhance the therapeutic benefit and patient care. The company was incorporated in 2007 and is based in Encinitas, California.

Advanced Diabetes Supply is an accredited medical supply company that provides diabetes supplies and helps patients with insurance, shipping and more.

Grifols is a global healthcare company. Grifols operates in three segments: Bioscience, Hospital, and Diagnostic. The Bioscience segment engages in the research, development, production, and commercialization of plasma derivates. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing diagnostics products for laboratory analysis, including products for hospital blood banks and transfusion centers.

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

Genome Medical is a national telegenomics technology, services, and strategy company bringing genomic medicine to everyday care. Through our nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. We also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.

Kimia Corporations is primarily engaged in commercial physical and biological research and development on a contract or fee basis.

HQP cultivates, produces, and manufactures high-quality cannabis products in the California market. HQP's management has significant experience in cannabis agronomy, as well as scaling businesses, maximizing shareholder value, and taking companies to public offering through organic growth and strong Mergers and Acquisitions activity. Headquartered in Monterey California's famous “Cannabis Row”, Hi Quality Products was established in June 2018.

Opiant Pharmaceuticals, with its team of addiction experts, is headquartered in Santa Monica, California. The Company, formerly known as Lightlake Therapeutics, was founded in 2009 by the late Dr. David Sinclair based on his pioneering research demonstrating that opioid antagonists could be used as a symptom-driven treatment for alcoholism

Mindstrong is a mental health company using technology to help members access care whenever and wherever they need it and a clinical staff that delivers cognitive-based therapy and medication management through a smartphone app.

SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada.

Orca Bio is helping to deliver the promise of cell therapy to patients without compromise.

Nufactor, Inc. is the specialty pharmacy specializing in IVIG, SCIG and factor home infusion services and is dedicated to patients, healthcare professionals, and the chronic illnesses community

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.

Parnell Pharmaceuticals is a private company engaged in the development and marketing of RX and OTC products which are natural, clinically proven,physician formulated and nature refined. We are expanding and building a distribution network with brokers and experienced sales people based on a high commission structure.

twoXAR is an artificial intelligence-driven drug discovery company. They leverage their computational platform to identify promising drug candidates, validate & de-risk them through preclinical studies, and progress candidates to the clinic through industry and investor partnerships.

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY , POSIDUR™, ELADUR , and TRANSDUR -Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs

At Discovery Behavioral Health, we believe that everyone deserves a happy, rewarding life. That's why we connect people, professionals and payors through a seamless network of evidence-based treatment centers in communities nationwide. Because when acc...

Buy dental supplies, Equipment and Digital solutions at best prices. Highest quality specialty dental supplies. Superior Customer Service. 800-535-4535

Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone's lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by PhD scientists developing medical technologies for national defense applications at Sandia National Laboratories.

Healing Lives through the Miracle of Recovery Providing high-quality, low-cost substance abuse treatment, drug intervention, and recovery support services to more than 13,000 men, women, teens, and children throughout San Diego County

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral.The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus's ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.

Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. Cold Genesys acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.

Depomed, Inc. is an American specialty pharmaceutical company which mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California.

Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon currently is promoting Silenor , the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.

CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.

SICOR Inc. manufactures and markets generic injectable pharmaceutical products, active pharmaceutical ingredients (API), and generic biopharmaceuticals. The company's products include anti-inflammatories, antibiotics, oncolytics, analgesic, immunosuppressants, neuromuscular blocking agents, and muscle relaxants. SICOR Inc. was forrmerly known as Gensia Sicor, Inc. and changed its name to SICOR Inc. in June 1999. The company was founded in 1986 and is based in Irvine, California with an additional office in Washington, District Of Columbia. As of January 22, 2004, SICOR Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. Its DC Bead product candidate is a treatment for liver cancer, which is approved in 40 countries worldwide, including Europe and the United States. Ondansetron RapidFilm is an oral thin film formulation of ondansetron used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. SCV-07 is being developed for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck and for the treatment of hepatitis C virus (HCV). Thymalfasin is being developed in an ongoing clinical trial for improvement of Influenza A (H1N1) vaccination.

Sonoma Pharmaceuticals is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company's products, over 100 SKUs commercialized worldwide, are used to treat patients in advanced wound management, dermatology, women's health and animal health; addressing the unmet medical needs of these markets-while raising the standard of patient care and lowering overall healthcare costs.

Gauss Surgical is a med-tech company that develops a vision-based platform for accurate and real-time measurement of surgical blood loss. They develop beautiful applications for iOS backed by sophisticated algorithms and a robust, HIPAA-compliant technical stack to enable real-time monitoring during surgery. It was incorporated in 2011 and is headquartered in Menlo Park, California.

Davida CoadyApril 15, 1938 - May 3, 2018Physician, Activist and Founder of Options Recovery Services The Options family - board, staff, supporters, clients, and the thousands of graduates over the past 21 years, from the streets of Berkeley and Oakland...

IntelliGuard is the leader in Radio Frequency Identification (#RFID) inventory management solutions for the pharmaceutical supply chain in hospitals.